{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:02:17Z","timestamp":1789621337972,"version":"build-2803163510"},"reference-count":215,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science and Technology Council","award":["114-2320-B-002-047-MY3"],"award-info":[{"award-number":["114-2320-B-002-047-MY3"]}]},{"award":["114-2320-B-002-047-MY3"],"award-info":[{"award-number":["114-2320-B-002-047-MY3"]}],"id":[{"id":"https:\/\/ror.org\/02kv4zf79","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antioxidants"],"abstract":"<jats:p>Oxidative stress is a central and well-established driver of cardiovascular disease, contributing to mitochondrial dysfunction, endothelial injury, inflammatory activation, and progressive myocardial and vascular remodeling. Although the major endogenous sources of cardiovascular reactive oxygen species (ROS), including NADPH oxidases, mitochondrial electron transport chain leakage, and uncoupled nitric oxide synthase, are well characterized, an additional and underappreciated contributor has recently emerged: cytochrome P450 2D6 (CYP2D6), an enzyme classically regarded as a hepatic drug-metabolizing protein. Accumulating evidence indicates that CYP2D6 is expressed extrahepatically in cardiac, vascular, and neural tissue, where uncoupled catalytic cycling is proposed to generate ROS independently of its canonical xenobiotic-metabolizing role, although direct experimental evidence for this pathway in human cardiac and vascular tissue remains limited. CYP2D6-derived oxidative processes may interact with mitochondrial respiratory function, endothelial nitric oxide bioavailability, and redox-sensitive inflammatory pathways, potentially contributing to cardiovascular vulnerability under specific genetic or pathological conditions. Critically, the magnitude of this oxidative contribution is not fixed: it is dynamically shaped by inherited CYP2D6 genetic variation, with poor and ultra-rapid metabolizer phenotypes exhibiting divergent oxidative burden and pharmacokinetic vulnerability, and is further amplified by polypharmacy, multimorbidity, and inflammation-driven phenoconversion, whereby clinically expressed CYP2D6 activity diverges from inherited genotype in ways that intensify redox imbalance. These dynamics are particularly relevant in East Asian populations, where the decreased-function CYP2D6*10 allele is highly prevalent. In this narrative, hypothesis-generating review, we integrate evidence from pharmacogenomics, redox biology, and cardiovascular pharmacology to propose a conceptual framework that reframes CYP2D6 as a genetically and pharmacologically tunable node within cardiovascular redox biology. We further examine emerging redox biomarkers, multi-omics platforms, and AI-assisted modeling as translational strategies for capturing this dynamic oxidative risk in real time. This framework supports a shift from static genotype-guided prescribing toward oxidative-risk-informed, adaptive cardiovascular precision medicine. Importantly, our focus on CYP2D6 should not be interpreted as evidence that it is a major cardiovascular CYP isozyme or an established driver of cardiovascular pathology. Rather, CYP2D6 is examined here as a deliberately hypothesis-generating candidate whose unusually strong pharmacogenetic variability, clinically important cardiovascular drug substrates, dynamic susceptibility to phenoconversion, extrahepatic expression, and mechanistically plausible links to endogenous substrate metabolism and CYP-associated ROS generation provide a convergent rationale for focused investigation. The mechanistic framework proposed in this review has not yet been experimentally and prospectively validated and should not be applied directly to clinical decision-making without supporting clinical data.<\/jats:p>","DOI":"10.3390\/antiox15091154","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:11:22Z","timestamp":1789049482000},"page":"1154","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CYP2D6 as an Emerging Endogenous Oxidative Stress Modulator in Cardiovascular Disease: Genetic, Pharmacological, and Redox Perspectives"],"prefix":"10.3390","volume":"15","author":[{"given":"Cheng-Wu","family":"Yang","sequence":"first","affiliation":[{"name":"Graduate Institute and Department of Physiology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hua","family":"Chen","sequence":"additional","affiliation":[{"name":"Graduate Institute and Department of Physiology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9593-4062","authenticated-orcid":false,"given":"Tzong-Shyuan","family":"Lee","sequence":"additional","affiliation":[{"name":"Graduate Institute and Department of Physiology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: Update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1161\/CIRCULATIONAHA.106.655688","article-title":"The cardiovascular disease continuum validated: Clinical evidence of improved patient outcomes: Part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease)","volume":"114","author":"Dzau","year":"2006","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrg.2016.86","article-title":"Towards precision medicine","volume":"17","author":"Ashley","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3109\/07853890.2011.653399","article-title":"Advancing management of hypertension through pharmacogenomics","volume":"44","author":"Johnson","year":"2012","journal-title":"Ann. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.109.914820","article-title":"Pharmacogenomics: The genetics of variable drug responses","volume":"123","author":"Roden","year":"2011","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1161\/CIRCRESAHA.117.310782","article-title":"Emerging role of precision medicine in cardiovascular disease","volume":"122","author":"Leopold","year":"2018","journal-title":"Circ. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/gim.2016.80","article-title":"Prediction of CYP2D6 phenotype from genotype across world populations","volume":"19","author":"Gaedigk","year":"2017","journal-title":"Genet. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00008571-200303000-00007","article-title":"Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6","volume":"13","author":"Yu","year":"2003","journal-title":"Pharmacogenetics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tips.2004.02.007","article-title":"Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future","volume":"25","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/cpt.910","article-title":"The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database","volume":"103","author":"Gaedigk","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/cpt.1409","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy","volume":"106","author":"Brown","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","article-title":"The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype","volume":"83","author":"Gaedigk","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_15","unstructured":"Pratt, V.M., Scott, S.A., and Pirmohamed, M. (2026, August 03). CYP2D6 Overview: Allele and Phenotype Frequencies, Medical Genetics Summaries, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK574601\/."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.fpc.0000239974.69464.f2","article-title":"CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure","volume":"17","author":"Sistonen","year":"2007","journal-title":"Pharmacogenet. Genom."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/clpt.2008.172","article-title":"Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users","volume":"85","author":"Bijl","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/11318070-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/gim.2016.87","article-title":"Standardizing terms for clinical pharmacogenetic test results: Consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)","volume":"19","author":"Caudle","year":"2017","journal-title":"Genet. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: From bench to byte\u2014An update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1124\/dmd.114.061093","article-title":"Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: Hypothesis with implications for personalized medicine","volume":"43","author":"Shah","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"115421","DOI":"10.1016\/j.addr.2024.115421","article-title":"Model-informed precision dosing: State of the art and future perspectives","volume":"215","author":"Minichmayr","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/cpt.2354","article-title":"How to integrate CYP2D6 phenoconversion into clinical pharmacogenetics: A tutorial","volume":"110","author":"Cicali","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Klomp, S.D., Manson, M.L., Guchelaar, H.-J., and Swen, J.J. (2020). Phenoconversion of cytochrome P450 metabolism: A systematic review. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092890"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2022.9805","article-title":"Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: The PRIME Care randomized clinical trial","volume":"328","author":"Oslin","year":"2022","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clpt.2006.03.013","article-title":"Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment","volume":"80","author":"Borges","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/1871525715666170529093442","article-title":"Polypharmacy in cardiovascular medicine: Problems and promises!","volume":"15","author":"Abolbashari","year":"2017","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1517\/17425255.1.4.629","article-title":"Regulation of drug metabolism and disposition during inflammation and infection","volume":"1","author":"Renton","year":"2005","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"109C","DOI":"10.1016\/0002-9149(92)91367-D","article-title":"Drug-patient interactions and their relevance in the treatment of heart failure","volume":"70","author":"Johnston","year":"1992","journal-title":"Am. J. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1161\/01.RES.0000258450.44413.96","article-title":"Mitochondrial dysfunction in atherosclerosis","volume":"100","author":"Madamanchi","year":"2007","journal-title":"Circ. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cell.2014.02.012","article-title":"Individualized medicine from prewomb to tomb","volume":"157","author":"Topol","year":"2014","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1503\/jpn.120133","article-title":"Cytochrome P450-mediated drug metabolism in the brain","volume":"38","author":"Miksys","year":"2013","journal-title":"J. Psychiatry Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2174\/138920008783571792","article-title":"Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure","volume":"9","author":"Zordoky","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.pharmthera.2005.05.011","article-title":"Cytochrome P450 enzymes: Central players in cardiovascular health and disease","volume":"112","author":"Elbekai","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/hh2101.099268","article-title":"Cytochrome P450 and vascular homeostasis","volume":"89","author":"Fleming","year":"2001","journal-title":"Circ. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1161\/CIRCULATIONAHA.105.602532","article-title":"Endothelial nitric oxide synthase in vascular disease: From marvel to menace","volume":"113","year":"2006","journal-title":"Circulation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.ki.5002394","article-title":"Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension","volume":"72","author":"Capdevila","year":"2007","journal-title":"Kidney Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/17425255.2022.2114344","article-title":"Cardiomyocyte-specific CYP2J2 and its therapeutic implications","volume":"18","author":"Valencia","year":"2022","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.113.053389","article-title":"Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes","volume":"41","author":"Evangelista","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1081\/DMR-120034149","article-title":"The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics","volume":"36","author":"Miksys","year":"2004","journal-title":"Drug Metab. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.biopsycho.2005.11.013","article-title":"The role of vagal function in the risk for cardiovascular disease and mortality","volume":"74","author":"Thayer","year":"2007","journal-title":"Biol. Psychol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1152\/japplphysiol.00182.2010","article-title":"Point: Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension","volume":"109","author":"Esler","year":"2010","journal-title":"J. Appl. Physiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/FPC.0b013e32801a3c10","article-title":"CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited","volume":"17","author":"Ozdemir","year":"2007","journal-title":"Pharmacogenet. Genom."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1471-4159.2011.07339.x","article-title":"Cytochrome P450 mediates dopamine formation in the brain in vivo","volume":"118","author":"Bromek","year":"2011","journal-title":"J. Neurochem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1161\/HYPERTENSIONAHA.110.157727","article-title":"Dopamine receptors: Important antihypertensive counterbalance against hypertensive factors","volume":"57","author":"Zeng","year":"2011","journal-title":"Hypertension"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S1734-1140(13)71513-5","article-title":"Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters","volume":"65","author":"Haduch","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1021\/tx700079z","article-title":"Cytochrome P450 and chemical toxicology","volume":"21","author":"Guengerich","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"130595","DOI":"10.1016\/j.bbagen.2024.130595","article-title":"Uncoupling of cytochrome P450 2B6 and stimulation of reactive oxygen species production in pharmacogenomic alleles affected by interethnic variability","volume":"1868","author":"Yamoune","year":"2024","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.taap.2004.01.018","article-title":"Mechanisms that regulate production of reactive oxygen species by cytochrome P450","volume":"199","author":"Zangar","year":"2004","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1021\/cr0307143","article-title":"Structure and chemistry of cytochrome P450","volume":"105","author":"Denisov","year":"2005","journal-title":"Chem. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"10964","DOI":"10.1021\/acscatal.8b03401","article-title":"Mechanisms of cytochrome P450-catalyzed oxidations","volume":"8","author":"Guengerich","year":"2018","journal-title":"ACS Catal."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1161\/CIRCRESAHA.116.309326","article-title":"Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis","volume":"120","author":"Xia","year":"2017","journal-title":"Circ. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.pharmthera.2009.12.002","article-title":"Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases","volume":"125","author":"Zordoky","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s40262-021-01064-4","article-title":"Impact of inflammation on cytochromes P450 activity in pediatrics: A systematic review","volume":"60","author":"Lenoir","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/acem.12431","article-title":"The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness","volume":"21","author":"Monte","year":"2014","journal-title":"Acad. Emerg. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/pr.111.004697","article-title":"Serotonin and blood pressure regulation","volume":"64","author":"Watts","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.pharmthera.2005.12.004","article-title":"5-hydroxytryptamine receptors in the human cardiovascular system","volume":"111","author":"Kaumann","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0025-6196(12)62272-1","article-title":"The central autonomic network: Functional organization, dysfunction, and perspective","volume":"68","author":"Benarroch","year":"1993","journal-title":"Mayo Clin. Proc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jacc.2009.03.061","article-title":"Sympathetic nervous system activation in human heart failure: Clinical implications of an updated model","volume":"54","author":"Floras","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijcard.2009.09.543","article-title":"The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors","volume":"141","author":"Thayer","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrcardio.2016.181","article-title":"Depression and coronary heart disease","volume":"14","author":"Carney","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20081386","article-title":"How mitochondria produce reactive oxygen species","volume":"417","author":"Murphy","year":"2009","journal-title":"Biochem. J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1152\/physrev.00029.2006","article-title":"Nitric oxide and peroxynitrite in health and disease","volume":"87","author":"Pacher","year":"2007","journal-title":"Physiol. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/01.ATV.0000150649.39934.13","article-title":"Oxidative stress and vascular disease","volume":"25","author":"Madamanchi","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","article-title":"Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects","volume":"116","author":"Sim","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1101\/gad.269894.115","article-title":"Mitochondrial biogenesis and dynamics in the developing and diseased heart","volume":"29","author":"Dorn","year":"2015","journal-title":"Genes Dev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/cvr\/cvq231","article-title":"Cardiac mitochondria and arrhythmias","volume":"88","author":"Brown","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10741-012-9340-0","article-title":"Mitochondrial dysfunction in heart failure","volume":"18","author":"Rosca","year":"2013","journal-title":"Heart Fail. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMra063052","article-title":"The failing heart\u2014An engine out of fuel","volume":"356","author":"Neubauer","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.192.7.1001","article-title":"Reactive oxygen species (ROS)-induced ROS release: A new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes","volume":"192","author":"Zorov","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.freeradbiomed.2011.06.033","article-title":"Cross talk between mitochondria and NADPH oxidases","volume":"51","author":"Dikalov","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"11389","DOI":"10.1073\/pnas.1513047112","article-title":"Mitochondrial calcium overload is a key determinant in heart failure","volume":"112","author":"Santulli","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/415198a","article-title":"Cardiac excitation-contraction coupling","volume":"415","author":"Bers","year":"2002","journal-title":"Nature"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"H2181","DOI":"10.1152\/ajpheart.00554.2011","article-title":"Oxidative stress and heart failure","volume":"301","author":"Tsutsui","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.RES.85.4.357","article-title":"Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium","volume":"85","author":"Ide","year":"1999","journal-title":"Circ. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41431-024-01648-1","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP2C19 and non-SSRI\/non-TCA antidepressants","volume":"32","author":"Beunk","year":"2024","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_78","first-page":"101781","article-title":"Influence of CYP2D6 phenotype on the pharmacokinetics and pharmacodynamics of tramadol in patients treated for post-operative pain management","volume":"45","author":"Percevault","year":"2026","journal-title":"Anaesth. Crit. Care Pain Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/cts.12692","article-title":"Standardizing CYP2D6 genotype to phenotype translation: Consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group","volume":"13","author":"Caudle","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/a-1288-1061","article-title":"Review and consensus on pharmacogenomic testing in psychiatry","volume":"54","author":"Bousman","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.pnpbp.2005.11.007","article-title":"The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients","volume":"30","author":"Ueda","year":"2006","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatry"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/cpt.3351","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 genotypes and beta-blocker therapy","volume":"116","author":"Duarte","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/14622416.2025.2597182","article-title":"Understanding variation in metoprolol response: CYP2D6, drug interactions, and phenoconversion","volume":"26","author":"Azizi","year":"2025","journal-title":"Pharmacogenomics"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/clpt.2014.62","article-title":"Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate","volume":"96","author":"Hamadeh","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14622416.2025.2591596","article-title":"From genomics to clinic: The transformative impact of AI in pharmacogenomics and personalized medicine","volume":"26","author":"Jakka","year":"2025","journal-title":"Pharmacogenomics"},{"key":"ref_86","first-page":"879","article-title":"Drug-drug-gene interactions in cardiovascular medicine","volume":"15","author":"Asiimwe","year":"2022","journal-title":"Pharmgenom. Pers. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/ajhp\/zxae110","article-title":"Recommendations for pharmacogenetic testing in clinical practice guidelines in the US","volume":"81","author":"Hertz","year":"2024","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_88","first-page":"1","article-title":"Implementing pharmacogenetics in clinical trials: Considerations about current methodological, ethical, and regulatory challenges","volume":"17","author":"Borobia","year":"2024","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev.pharmtox.46.120604.141059","article-title":"Regulation of drug-metabolizing enzymes and transporters in inflammation","volume":"46","author":"Aitken","year":"2006","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1517\/17425255.4.8.1065","article-title":"The effect of chronic renal failure on drug metabolism and transport","volume":"4","author":"Dreisbach","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/clpt.2008.59","article-title":"Emerging evidence of the impact of kidney disease on drug metabolism and transport","volume":"83","author":"Nolin","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/14740338.2013.827660","article-title":"Clinical consequences of polypharmacy in elderly","volume":"13","author":"Maher","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/BF03261926","article-title":"Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs","volume":"51","author":"Dostalek","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1172\/JCI21625","article-title":"Increased oxidative stress in obesity and its impact on metabolic syndrome","volume":"114","author":"Furukawa","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1111\/j.1582-4934.2009.00733.x","article-title":"Inflammation and frailty measures in older people","volume":"13","author":"Hubbard","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/cpt.659","article-title":"Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future","volume":"101","author":"Darwich","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.clpt.2005.07.004","article-title":"Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: A prospective clinical study","volume":"78","author":"Fux","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1056\/NEJM198212163072505","article-title":"Oxidation phenotype\u2014A major determinant of metoprolol metabolism and response","volume":"307","author":"Lennard","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.5599\/admet.2961","article-title":"Elucidating CYP2D6-driven metabolism and hepatotoxic bioactivation of metoprolol in plateable human and animal hepatocytes","volume":"13","author":"Pu","year":"2025","journal-title":"ADMET DMPK"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s11095-017-2104-8","article-title":"CYP2D6 genetic variation and beta-blocker maintenance dose in patients with heart failure","volume":"34","author":"Luzum","year":"2017","journal-title":"Pharm. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/bcp.14247","article-title":"CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis","volume":"86","author":"Meloche","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.tips.2008.04.001","article-title":"Mitochondrial off targets of drug therapy","volume":"29","author":"Wallace","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1007\/BF01409476","article-title":"Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound","volume":"38","author":"Neugebauer","year":"1990","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/eurheartj\/17.suppl_B.24","article-title":"Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection","volume":"17","author":"Feuerstein","year":"1996","journal-title":"Eur. Heart J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2217\/pgs.11.20","article-title":"Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics","volume":"12","author":"Sehrt","year":"2011","journal-title":"Pharmacogenomics"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1592\/phco.27.6.874","article-title":"Pharmacogenetics of beta-blockers","volume":"27","author":"Shin","year":"2007","journal-title":"Pharmacotherapy"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5414\/CPP44344","article-title":"Nebivolol: A review of its clinical and pharmacological characteristics","volume":"44","author":"Gielen","year":"2006","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1056\/NEJM199409223311207","article-title":"Risks and benefits of antiarrhythmic therapy","volume":"331","author":"Roden","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199121010-00001","article-title":"Clinical pharmacokinetics of propafenone","volume":"21","author":"Hii","year":"1991","journal-title":"Clin. Pharmacokinet."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Tran, Q.T., Baek, I.-H., Han, N.-Y., Yun, H.-Y., and Chae, J.-W. (2022). The effect of CYP2D6 phenotypes on the pharmacokinetics of propafenone: A systematic review and meta-analysis. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14071446"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/0002-9149(92)90355-3","article-title":"Beta-blocking effect of propafenone based on spectral analysis of heart rate variability","volume":"70","author":"Lombardi","year":"1992","journal-title":"Am. J. Cardiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/FJC.0000000000001739","article-title":"Relevance of CYP2D6 in the efficacy and toxicity of flecainide in patients with atrial fibrillation: A cohort study","volume":"86","author":"Gil","year":"2025","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.amjcard.2019.12.041","article-title":"Use of flecainide for the treatment of atrial fibrillation","volume":"125","author":"Echt","year":"2020","journal-title":"Am. J. Cardiol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1124\/pr.110.003723","article-title":"Drug-induced long QT syndrome","volume":"62","author":"Kannankeril","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/17431380410032445","article-title":"Drug-induced QT interval prolongation: Regulatory perspectives and drug development","volume":"36","author":"Shah","year":"2004","journal-title":"Ann. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/cpt.630","article-title":"The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems","volume":"102","author":"Luzum","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/14622416.3.2.229","article-title":"CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants","volume":"3","author":"Bradford","year":"2002","journal-title":"Pharmacogenomics"},{"key":"ref_122","first-page":"687","article-title":"Effects of 22 novel CYP2D6 variants found in Chinese population on the metabolism of dapoxetine","volume":"10","author":"Xu","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s12012-024-09880-3","article-title":"The potential role of CYP2D6*10 (c.100 C>T) gene polymorphism in kidney injury of patients with hypertension complicated with non-elevated cystatin C","volume":"24","author":"Jiang","year":"2024","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/03602530903118729","article-title":"New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme","volume":"41","author":"Wang","year":"2009","journal-title":"Drug Metab. Rev."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3109\/09540261.2013.825581","article-title":"Complexities of CYP2D6 gene analysis and interpretation","volume":"25","author":"Gaedigk","year":"2013","journal-title":"Int. Rev. Psychiatry"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/17425255.2022.2160317","article-title":"CYP2D6 pharmacogenetics and phenoconversion in personalized medicine","volume":"18","author":"Nahid","year":"2022","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Stoleru, I.-M., Mocan, M., Cri\u0219an, C.-H.-E., Niculae, L.E., and Chira, R.I. (2025). Prognostic value of liver stiffness in patients with heart failure: A systematic review and meta-analysis. BMC Cardiovasc. Disord., 25.","DOI":"10.1186\/s12872-025-05289-0"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3109\/03602539709002246","article-title":"Regulation of cytochromes P450 during inflammation and infection","volume":"29","author":"Morgan","year":"1997","journal-title":"Drug Metab. Rev."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"7A","DOI":"10.1016\/S0002-9149(02)03144-2","article-title":"Role of oxidative stress in atherosclerosis","volume":"91","author":"Harrison","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"74","author":"January","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","article-title":"Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies","volume":"52","author":"Octavia","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1177\/02698811241278844","article-title":"Clinical effects of CYP2D6 phenoconversion in patients with psychosis","volume":"38","author":"Breddels","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"121","DOI":"10.14744\/hf.2023.2023.0047","article-title":"Phenoconversion and in vivo phenotyping of hepatic cytochrome P450: Implications in predictive precision medicine and personalized therapy","volume":"6","author":"Ali","year":"2025","journal-title":"Hepatol. Forum"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s11096-023-01588-8","article-title":"Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: A retrospective cohort study","volume":"45","author":"Frantz","year":"2023","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1056-4993(18)30135-4","article-title":"Cytochrome P450-mediated drug interactions","volume":"9","author":"Flockhart","year":"2000","journal-title":"Child Adolesc. Psychiatr. Clin. N. Am."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199700321-00003","article-title":"Clinically relevant pharmacology of selective serotonin reuptake inhibitors: An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism","volume":"32","author":"Preskorn","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis: From pathophysiology to practice","volume":"54","author":"Libby","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Rodieux, F., Storelli, F., Curtin, F., Manzano, S., Gervaix, A., Posfay-Barbe, K.M., Desmeules, J., Daali, Y., and Samer, C.F. (2023). Evaluation of pupillometry for CYP2D6 phenotyping in children treated with tramadol. Pharmaceuticals, 16.","DOI":"10.3390\/ph16091227"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbrc.2010.02.162","article-title":"Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system","volume":"396","author":"Sim","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40262-025-01494-4","article-title":"Influence of ageing on the pharmacodynamics and pharmacokinetics of chronically administered medicines in geriatric patients: A review","volume":"64","author":"Ngcobo","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1124\/dmd.107.015511","article-title":"Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes","volume":"35","author":"Aitken","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1124\/dmd.111.038679","article-title":"Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture","volume":"39","author":"Dickmann","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0026-895X(25)08588-8","article-title":"Suppression of the constitutive expression of cytochrome P-450 2C11 by cytokines and interferons in primary cultures of rat hepatocytes: Comparison with induction of acute-phase genes and demonstration that CYP2C11 promoter sequences are involved in the suppressive response to interleukins 1 and 6","volume":"47","author":"Chen","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1172\/JCI26283","article-title":"Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation","volume":"116","author":"Zhou","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1161\/01.RES.0000043825.01705.1B","article-title":"Inflammatory mediators and the failing heart: Past, present, and the foreseeable future","volume":"91","author":"Mann","year":"2002","journal-title":"Circ. Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"107627","DOI":"10.1016\/j.pharmthera.2020.107627","article-title":"Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment","volume":"215","author":"Chhun","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/cpt.2146","article-title":"Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva cocktail","volume":"109","author":"Lenoir","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.critrevonc.2003.04.004","article-title":"Understanding and preventing drug interactions in elderly patients","volume":"48","author":"Delafuente","year":"2003","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/CIRCULATIONAHA.108.190769","article-title":"Depression and coronary heart disease: Recommendations for screening, referral, and treatment: A science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Psychiatric Association","volume":"118","author":"Lichtman","year":"2008","journal-title":"Circulation"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1389200023338017","article-title":"Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update","volume":"3","author":"Hemeryck","year":"2002","journal-title":"Curr. Drug Metab."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/009127000004000108","article-title":"CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: Intraindividual variability and plasma concentration correlations","volume":"40","author":"Alfaro","year":"2000","journal-title":"J. Clin. Pharmacol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1111\/bcp.13741","article-title":"The impact of CYP2D6 mediated drug-drug interaction: A systematic review on a combination of metoprolol and paroxetine\/fluoxetine","volume":"84","author":"Bahar","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/pds.4200","article-title":"The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): Co-medication of metoprolol and paroxetine or fluoxetine in the elderly","volume":"26","author":"Bahar","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1034\/j.1600-0773.2003.930301.x","article-title":"Doxorubicin-induced cardiac mitochondrionopathy","volume":"93","author":"Wallace","year":"2003","journal-title":"Pharmacol. Toxicol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management","volume":"109","author":"Yeh","year":"2004","journal-title":"Circulation"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200443130-00004","article-title":"Clinical pharmacology of tramadol","volume":"43","author":"Grond","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.clpt.6100152","article-title":"Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes","volume":"82","author":"Stamer","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0009-9236(96)90211-8","article-title":"The hypoalgesic effect of tramadol in relation to CYP2D6","volume":"60","author":"Poulsen","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_162","first-page":"395","article-title":"Tramadol, pharmacology, side effects, and serotonin syndrome: A review","volume":"18","author":"Beakley","year":"2015","journal-title":"Pain Physician"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1067\/mcp.2002.127111","article-title":"Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects","volume":"72","author":"Wuttke","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1113\/JP270526","article-title":"Predicting drug-induced QT prolongation and torsades de pointes","volume":"594","author":"Roden","year":"2016","journal-title":"J. Physiol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/cvr\/cvac134","article-title":"Mitochondrial calcium and reactive oxygen species in cardiovascular disease","volume":"119","author":"Murphy","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.freeradbiomed.2011.05.004","article-title":"Reactive oxygen species in cardiovascular disease","volume":"51","author":"Sugamura","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"82","DOI":"10.64719\/pb.15425","article-title":"Personalizing treatment for acute alcoholic hallucinosis: Clinical utility of integrated pharmacogenetic testing, metabolic phenotyping, and microRNA biomarkers","volume":"56","author":"Skryabin","year":"2026","journal-title":"Psychopharmacol. Bull."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/s41587-019-0217-9","article-title":"Accurate circular consensus long-read sequencing improves variant detection and assembly of a human genome","volume":"37","author":"Wenger","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/03602530600952206","article-title":"Pharmacogenetic screening of the gene deletion and duplications of CYP2D6","volume":"39","author":"Meijerman","year":"2007","journal-title":"Drug Metab. Rev."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1021\/ac202028g","article-title":"High-throughput droplet digital PCR system for absolute quantitation of DNA copy number","volume":"83","author":"Hindson","year":"2011","journal-title":"Anal. Chem."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1124\/dmd.111.040832","article-title":"Frequency of undetected CYP2D6 hybrid genes in clinical samples: Impact on phenotype prediction","volume":"40","author":"Black","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/cpt.3044","article-title":"PharmVar tutorial on CYP2D6 structural variation testing and recommendations on reporting","volume":"114","author":"Turner","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41569-020-00477-1","article-title":"Systems biology in cardiovascular disease: A multiomics approach","volume":"18","author":"Joshi","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrg2484","article-title":"RNA-Seq: A revolutionary tool for transcriptomics","volume":"10","author":"Wang","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/dmd.107.018747","article-title":"Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer","volume":"36","author":"Morgan","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrm3314","article-title":"Innovation: Metabolomics: The apogee of the omics trilogy","volume":"13","author":"Patti","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMra1104901","article-title":"The human plasma lipidome","volume":"365","author":"Quehenberger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1161\/CIRCULATIONAHA.113.002500","article-title":"Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study","volume":"129","author":"Stegemann","year":"2014","journal-title":"Circulation"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1517\/17425255.2011.586337","article-title":"Cytochrome P450-mediated cardiovascular drug interactions","volume":"7","author":"Scheen","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1089\/ars.2015.6247","article-title":"The Redox Code","volume":"23","author":"Jones","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.freeradbiomed.2009.12.022","article-title":"Reactive oxygen species, cellular redox systems, and apoptosis","volume":"48","author":"Circu","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1158\/1055-9965.EPI-05-0456","article-title":"Complementing the genome with an \u201cexposome\u201d: The outstanding challenge of environmental exposure measurement in molecular epidemiology","volume":"14","author":"Wild","year":"2005","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1126\/science.aay3164","article-title":"The exposome and health: Where chemistry meets biology","volume":"367","author":"Vermeulen","year":"2020","journal-title":"Science"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/heartjnl-2017-311198","article-title":"Machine learning in cardiovascular medicine: Are we there yet?","volume":"104","author":"Shameer","year":"2018","journal-title":"Heart"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/4551054a","article-title":"Systems biology: Metabonomics","volume":"455","author":"Nicholson","year":"2008","journal-title":"Nature"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.2017.18391","article-title":"Big data and machine learning in health care","volume":"319","author":"Beam","year":"2018","journal-title":"JAMA"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/jamia\/ocw042","article-title":"Opportunities and challenges in developing risk prediction models with electronic health records data: A systematic review","volume":"24","author":"Goldstein","year":"2017","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1016\/j.jacc.2018.03.521","article-title":"Artificial intelligence in cardiology","volume":"71","author":"Johnson","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrd.2016.32","article-title":"Emerging applications of metabolomics in drug discovery and precision medicine","volume":"15","author":"Wishart","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"37","DOI":"10.18203\/2349-3259.ijct20161408","article-title":"In silico clinical trials: How computer simulation will transform the biomedical industry","volume":"3","author":"Viceconti","year":"2016","journal-title":"Int. J. Clin. Trials"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1093\/eurheartj\/ehaa159","article-title":"The \u2018Digital Twin\u2019 to enable the vision of precision cardiology","volume":"41","author":"Margara","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/jamia.2001.0080527","article-title":"Clinical decision support systems for the practice of evidence-based medicine","volume":"8","author":"Sim","year":"2001","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1016\/j.jacc.2017.03.571","article-title":"Artificial intelligence in precision cardiovascular medicine","volume":"69","author":"Krittanawong","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/17512433.2018.1501271","article-title":"Precision dosing in clinical medicine: Present and future","volume":"11","author":"Polasek","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J. Intern. Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00007691-200502000-00004","article-title":"Cost-effectiveness of therapeutic drug monitoring: A systematic review","volume":"27","author":"Touw","year":"2005","journal-title":"Ther. Drug Monit."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/CIRCRESAHA.122.322389","article-title":"Wearable devices in cardiovascular medicine","volume":"132","author":"Hughes","year":"2023","journal-title":"Circ. Res."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Shaffer, F., and Ginsberg, J.P. (2017). An overview of heart rate variability metrics and norms. Front. Public Health, 5.","DOI":"10.3389\/fpubh.2017.00258"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1901183","article-title":"Large-scale assessment of a smartwatch to identify atrial fibrillation","volume":"381","author":"Perez","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.bjp.0705776","article-title":"Measuring reactive species and oxidative damage in vivo and in cell culture: How should you do it and what do the results mean?","volume":"142","author":"Halliwell","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1373\/clinchem.2005.061408","article-title":"Biomarkers of oxidative damage in human disease","volume":"52","author":"Rossi","year":"2006","journal-title":"Clin. Chem."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1089\/ars.2006.8.1865","article-title":"Redefining oxidative stress","volume":"8","author":"Jones","year":"2006","journal-title":"Antioxid. Redox Signal."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev-pharmtox-010814-124835","article-title":"Preemptive clinical pharmacogenetics implementation: Current programs in five US medical centers","volume":"55","author":"Dunnenberger","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/ACM.0b013e31817ec800","article-title":"Perspective: Prospective health care and the role of academic medicine: Lead, follow, or get out of the way","volume":"83","author":"Snyderman","year":"2008","journal-title":"Acad. Med."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/wsbm.144","article-title":"Systems biology and the future of medicine","volume":"3","author":"Loscalzo","year":"2011","journal-title":"WIREs Syst. Biol. Med."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/tpj.2017.21","article-title":"Cost-effectiveness of pharmacogenetic-guided treatment: Are we there yet?","volume":"17","author":"Verbelen","year":"2017","journal-title":"Pharmacogenom. J."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/14622416.5.5.571","article-title":"From pharmacogenetics to personalized medicine: A vital need for educating health professionals and the community","volume":"5","author":"Frueh","year":"2004","journal-title":"Pharmacogenomics"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.0306-5251.2001.01498.x","article-title":"Pharmacogenetics and pharmacogenomics","volume":"52","author":"Pirmohamed","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jmoldx.2021.05.013","article-title":"Recommendations for clinical CYP2D6 genotyping allele selection: A joint consensus recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy","volume":"23","author":"Pratt","year":"2021","journal-title":"J. Mol. Diagn."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1377\/hlthaff.2017.1624","article-title":"Precision medicine: From science to value","volume":"37","author":"Ginsburg","year":"2018","journal-title":"Health Aff."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/clpt.2011.306","article-title":"Adoption of pharmacogenomic testing by US physicians: Results of a nationwide survey","volume":"91","author":"Stanek","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Rodriguez, P., Kikerkov, E., Emmott, N., Lu, C.Y., and Hendricks-Sturrup, R.M. (2025). A systematic review of real-world evidence on the clinical relevance, characterization, and utility of CYP2D6 biomarker testing. J. Pharm. Pharm. Sci., 28.","DOI":"10.3389\/jpps.2025.14708"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"e1573403X334668","DOI":"10.2174\/011573403X334668241227074314","article-title":"Pharmacogenomics and its role in cardiovascular diseases: A narrative literature review","volume":"21","author":"Kayani","year":"2025","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bcp.12441","article-title":"Addressing phenoconversion: The Achilles\u2019 heel of personalized medicine","volume":"79","author":"Shah","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","article-title":"Multi-omics approaches to disease","volume":"18","author":"Hasin","year":"2017","journal-title":"Genome Biol."}],"container-title":["Antioxidants"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3921\/15\/9\/1154\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:12:25Z","timestamp":1789618345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3921\/15\/9\/1154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":215,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["antiox15091154"],"URL":"https:\/\/doi.org\/10.3390\/antiox15091154","relation":{},"ISSN":["2076-3921"],"issn-type":[{"value":"2076-3921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}